Phenotypes Associated with This Genotype

Genotype
MGI:5317912

• Allelic Composition: Tg(KRT5-rtTA)1Glk/0; Tg(tetO/CMV-Tslp)#Sfz/0
• Genetic Background: C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

increased susceptibility to autoimmune hemolytic anemia ( J:182756 )

• dox treated mutants develop autoimmune hemolytic anemia

abnormal B cell activation ( J:182756 )

• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses

increased B cell proliferation ( J:182756 )

• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [³H] thymidine incorporation, indicating increased proliferation potential

• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential

increased circulating interleukin-4 level ( J:182756 )

• dox treated mutants exhibit an increase in serum IL-4 levels

increased autoantibody level ( J:182756 )

• following dox treatment, mutants show the presence of anti-RBC-specific autoantibodies

hematopoietic system

increased susceptibility to autoimmune hemolytic anemia ( J:182756 )

• dox treated mutants develop autoimmune hemolytic anemia

decreased hematocrit ( J:182756 )

• following dox treatment, mutants show a decrease in hematocrit corresponding with the presence of anti-RBC-specific autoantibodies, consistent with onset of hemolytic anemia

abnormal B cell activation ( J:182756 )

• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses

increased B cell proliferation ( J:182756 )

• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [³H] thymidine incorporation, indicating increased proliferation potential

• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential

homeostasis/metabolism

increased circulating interleukin-4 level ( J:182756 )

• dox treated mutants exhibit an increase in serum IL-4 levels

cellular

increased B cell proliferation ( J:182756 )

• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [³H] thymidine incorporation, indicating increased proliferation potential

• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
autoimmune hemolytic anemia		DOID:718	OMIM:205700	J:182756